AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JAN 1 - (NewsRx.com & NewsRx.net) -- "Malignant astrocytoma is the most common primary brain tumor in adults. The median survival of patients with malignant astrocytomas (high-grade astrocytomas) is about 1-2 years, despite aggressive treatment that includes surgical resection, radiotherapy, and cytotoxic chemotherapy. Therefore, novel therapeutic approaches are needed to prolong survival," say researchers in Japan.
T. Kikuchi and colleagues, Jikei University, "investigated antitumor immunity conferred by the intratumoral injection of dendritic (DC) and irradiated glioma cells (IR-GC) in a mouse brain tumor model."
They reported that "[i]ntratumorally-injected DC migrated to the lymph nodes and elicited systemic immunity against autologous glioma cells. In a treatment model, intratumoral injection of DC and IR-GC prolonged the survival of brain tumor-bearing mice."
The researchers noted a reduction in efficacy "when studies were performed in mice depleted of CD8+ T cells."
"Administration of DC or IR-GC alone had no effect on survival of brain tumor-bearing mice. CTL ...
Source: HighBeam Research, Intratumoral injection of dendritic and irradiated glioma cells...